Suchergebnisse - "Golfinopoulos, V"

PubPharm (26)

1

3D volume growth rate evaluation in the EORTC-BTG-1320 clinical trial for recurrent WHO grade 2 and 3 meningiomas

enthalten in: Neuro-oncology | 2024

von Tabouret, E. | Furtner, J. | Graillon, T. | +13

2

Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform

enthalten in: Scientific reports | 2022

von Morfouace, M. | Novello, S. | Stevovic, A. | +15

3

Managing cancer patients during the COVID-19 pandemic : an ESMO multidisciplinary expert consensus

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2020

von Curigliano, G. | Banerjee, S. | Cervantes, A. | +76

4

A transatlantic perspective on the integration of immuno-oncology prognostic and predictive biomarkers in innovative clinical trial design

enthalten in: Seminars in cancer biology | 2018

von Morfouace, M. | Hewitt, S. | Salgado, R. | +8

5

Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (EORTC 26082)

enthalten in: Clinical cancer research | 2016

von Wick, W. | Gorlia, T. | Bady, P. | +23

6

Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)

enthalten in: Clinical cancer research | 2016

von Wick, W. | Gorlia, T. | Bady, P. | +23

7

EH1.1 Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion, an intergroup trial

enthalten in: Neuro-Oncology | 2016

von van den Bent, M. | Erridge, S. | Vogelbaum, M. | +7

8

OS5.3 Stability of actionable mutations in primary and recurrent glioblastomas

enthalten in: Neuro-Oncology | 2016

von Draaisma, K. | Taphoorn, M. | Weyerbrock, A. | +7

9

OS5.7 First results of the randomized phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact 1st recurrence grade II and III glioma

enthalten in: Neuro-Oncology | 2016

von Idbaih, A. | Clement, P. | Vos, F. | +7

10

OS5.1 Sequence of bevacizumab and lomustine in patients with first progression of a glioblastoma: phase II EORTC study 26101

enthalten in: Neuro-Oncology | 2016

von Wick, W. | Stupp, R. | Gorlia, T. | +7